{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:36Z","timestamp":1791644316657,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T00:00:00Z","timestamp":1144281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T00:00:00Z","timestamp":1144281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1038\/sj.leu.2404206","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T14:34:24Z","timestamp":1144334064000},"page":"971-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained"],"prefix":"10.1038","volume":"20","author":[{"given":"D P","family":"Steensma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R F","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J E","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T L","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H L","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G W","family":"DeWald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S H","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,6]]},"reference":[{"key":"BF2404206_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"K Yamaoka","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt III VE, Silvennoinen O, O'Shea JJ . The Janus kinases (Jaks). Genome Biol 2004; 5: 253.","journal-title":"Genome Biol"},{"key":"BF2404206_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R . The STATs of cancer \u2013 new molecular targets come of age. Nat Rev Cancer 2004; 4: 97\u2013105.","journal-title":"Nat Rev Cancer"},{"key":"BF2404206_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI0215644","volume":"109","author":"CW Schindler","year":"2002","unstructured":"Schindler CW . Series introduction. JAK-STAT signaling in human disease. J Clin Invest 2002; 109: 1133\u20131137.","journal-title":"J Clin Invest"},{"key":"BF2404206_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1034\/j.1600-0609.2001.t01-1-00385.x","volume":"67","author":"K Spiekermann","year":"2001","unstructured":"Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F . Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol 2001; 67: 63\u201371.","journal-title":"Eur J Haematol"},{"key":"BF2404206_CR5","first-page":"2140","volume":"9","author":"K Spiekermann","year":"2003","unstructured":"Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W . Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 2003; 9: 2140\u20132150.","journal-title":"Clin Cancer Res"},{"key":"BF2404206_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0301-472X(01)00787-1","volume":"30","author":"K Spiekermann","year":"2002","unstructured":"Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W . Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002; 30: 262\u2013271.","journal-title":"Exp Hematol"},{"key":"BF2404206_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood.V99.1.252","volume":"99","author":"M Benekli","year":"2002","unstructured":"Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002; 99: 252\u2013257.","journal-title":"Blood"},{"key":"BF2404206_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/10428199709058334","volume":"28","author":"V Gouilleux-Gruart","year":"1997","unstructured":"Gouilleux-Gruart V, Debierre-Grockiego F, Gouilleux F, Capiod JC, Claisse JF, Delobel J et al. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma 1997; 28: 83\u201388.","journal-title":"Leuk Lymphoma"},{"key":"BF2404206_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF02981979","volume":"75","author":"K Kirito","year":"2002","unstructured":"Kirito K, Nagashima T, Ozawa K, Komatsu N . Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int J Hematol 2002; 75: 51\u201354.","journal-title":"Int J Hematol"},{"key":"BF2404206_CR10","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V95.12.3765","volume":"95","author":"JJ Schuringa","year":"2000","unstructured":"Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E . Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95: 3765\u20133770.","journal-title":"Blood"},{"key":"BF2404206_CR11","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood.V87.5.1692.1692","volume":"87","author":"V Gouilleux-Gruart","year":"1996","unstructured":"Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996; 87: 1692\u20131697.","journal-title":"Blood"},{"key":"BF2404206_CR12","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1073\/pnas.93.9.3963","volume":"93","author":"M Minami","year":"1996","unstructured":"Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA 1996; 93: 3963\u20133966.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2404206_CR13","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/j.1460-2075.1996.tb00734.x","volume":"15","author":"K Nakajima","year":"1996","unstructured":"Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996; 15: 3651\u20133658.","journal-title":"EMBO J"},{"key":"BF2404206_CR14","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","volume":"97","author":"ZQ Ning","year":"2001","unstructured":"Ning ZQ, Li J, Arceci RJ . Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001; 97: 3559\u20133567.","journal-title":"Blood"},{"key":"BF2404206_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.","journal-title":"Lancet"},{"key":"BF2404206_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387\u2013397.","journal-title":"Cancer Cell"},{"key":"BF2404206_CR17","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic J-P, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u20131148.","journal-title":"Nature"},{"key":"BF2404206_CR18","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779\u20131790.","journal-title":"N Engl J Med"},{"key":"BF2404206_CR19","doi-asserted-by":"publisher","first-page":"22788","DOI":"10.1074\/jbc.C500138200","volume":"280","author":"R Zhao","year":"2005","unstructured":"Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005; 280: 22788\u201322792.","journal-title":"J Biol Chem"},{"key":"BF2404206_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/10428190500301348","volume":"47","author":"ME Nelson","year":"2006","unstructured":"Nelson ME, Steensma DP . JAK2 V617F in myeloid disorders: What do we know now, and where are we headed? Leuk Lymphoma 2006; 47: 177\u2013194.","journal-title":"Leuk Lymphoma"},{"key":"BF2404206_CR21","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162\u20132168.","journal-title":"Blood"},{"key":"BF2404206_CR22","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u2018atypical\u2019 myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207\u20131209.","journal-title":"Blood"},{"key":"BF2404206_CR23","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Constantinescu SN . A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2005, 195\u2013200.","DOI":"10.1182\/asheducation-2005.1.195"},{"key":"BF2404206_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.4065\/80.7.947","volume":"80","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Gilliland DG . The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947\u2013958.","journal-title":"Mayo Clin Proc"},{"key":"BF2404206_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.4161\/cc.4.8.1872","volume":"4","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Gilliland DG . JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 2005; 4: 1053\u20131056.","journal-title":"Cell Cycle"},{"key":"BF2404206_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","volume":"130","author":"CN Harrison","year":"2005","unstructured":"Harrison CN . Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005; 130: 153\u2013165.","journal-title":"Br J Haematol"},{"key":"BF2404206_CR27","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1182\/blood-2005-03-1287","volume":"105","author":"K Kaushansky","year":"2005","unstructured":"Kaushansky K . On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005; 105: 4187\u20134190.","journal-title":"Blood"},{"key":"BF2404206_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","volume":"11","author":"C James","year":"2005","unstructured":"James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W . A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546\u2013554.","journal-title":"Trends Mol Med"},{"key":"BF2404206_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1385\/CBB:41:2:207","volume":"41","author":"EM Sandberg","year":"2004","unstructured":"Sandberg EM, Wallace TA, Godeny MD, VonDerLinden D, Sayeski PP . Jak2 tyrosine kinase: a true Jak of all trades? Cell Biochemistry and Biophysics 2004; 41: 207\u2013232.","journal-title":"Cell Biochemistry and Biophysics"},{"key":"BF2404206_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451\u2013458.","journal-title":"Br J Haematol"},{"key":"BF2404206_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1023\/A:1008375931236","volume":"10","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419\u20131432.","journal-title":"Ann Oncol"},{"key":"BF2404206_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/abio.2001.5313","volume":"296","author":"SH Kaufmann","year":"2001","unstructured":"Kaufmann SH . Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 2001; 296: 283\u2013286.","journal-title":"Anal Biochem"},{"key":"BF2404206_CR33","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1182\/blood.V86.8.2948.2948","volume":"86","author":"U Novak","year":"1995","unstructured":"Novak U, Harpur AG, Paradiso L, Kanagasundaram V, Jaworowski A, Wilks AF et al. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood 1995; 86: 2948\u20132956.","journal-title":"Blood"},{"key":"BF2404206_CR34","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532\u20131542.","journal-title":"Blood"},{"key":"BF2404206_CR35","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1182\/blood-2002-06-1800","volume":"101","author":"J Sohal","year":"2003","unstructured":"Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003; 101: 3188\u20133197.","journal-title":"Blood"},{"key":"BF2404206_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/BF02994002","volume":"73","author":"J Boultwood","year":"2001","unstructured":"Boultwood J, Wainscoat JS . Clonality in the myelodysplastic syndromes. Int J Hematol 2001; 73: 411\u2013415.","journal-title":"Int J Hematol"},{"key":"BF2404206_CR37","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370\u20133373.","journal-title":"Blood"},{"key":"BF2404206_CR38","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","volume":"106","author":"RL Levine","year":"2005","unstructured":"Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377\u20133379.","journal-title":"Blood"},{"key":"BF2404206_CR39","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","volume":"106","author":"LM Scott","year":"2005","unstructured":"Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920\u20132921.","journal-title":"Blood"},{"key":"BF2404206_CR40","doi-asserted-by":"crossref","unstructured":"Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2005: [E-pub October 10, 2005].","DOI":"10.1038\/sj.onc.1209163"},{"key":"BF2404206_CR41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.V64.2.427.427","volume":"64","author":"MJ Huang","year":"1984","unstructured":"Huang MJ, Li CY, Nichols WL, Young JH, Katzmann JA . Acute leukemia with megakaryocytic differentiation: a study of 12 cases identified immunocytochemically. Blood 1984; 64: 427\u2013439.","journal-title":"Blood"},{"key":"BF2404206_CR42","first-page":"122","volume":"40","author":"MB Amin","year":"1992","unstructured":"Amin MB, Maeda K, Carey JL, Babu RV, Raman BK . Megakaryoblastic termination of myeloproliferative disorders. Henry Ford Hosp Med J 1992; 40: 122\u2013126.","journal-title":"Henry Ford Hosp Med J"},{"key":"BF2404206_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2169\/internalmedicine1962.29.226","volume":"29","author":"K Kurashima","year":"1990","unstructured":"Kurashima K, Kawamura Y, Ohka T, Hayashi M, Matsuda T . Primary myelofibrosis terminating in megakaryoblastic crisis. Jpn J Med 1990; 29: 226\u2013229.","journal-title":"Jpn J Med"},{"key":"BF2404206_CR44","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/1097-0142(19871201)60:11<2654::AID-CNCR2820601114>3.0.CO;2-Q","volume":"60","author":"M Akahoshi","year":"1987","unstructured":"Akahoshi M, Oshimi K, Mizoguchi H, Okada M, Enomoto Y, Watanabe Y . Myeloproliferative disorders terminating in acute megakaryoblastic leukemia with chromosome 3q26 abnormality. Cancer 1987; 60: 2654\u20132661.","journal-title":"Cancer"},{"key":"BF2404206_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2257.1991.tb00247.x","volume":"13","author":"M Takahashi","year":"1991","unstructured":"Takahashi M, Koike T, Nagayama R, Fujiwara M, Koyama S, Ohnishi M et al. Myelodysplastic syndrome with myelofibrosis: myelodysplastic syndrome as a major primary disorder for acute myelofibrosis. Clin Lab Haematol 1991; 13: 17\u201323.","journal-title":"Clin Lab Haematol"},{"key":"BF2404206_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2141.1979.tb03734.x","volume":"43","author":"A Manoharan","year":"1979","unstructured":"Manoharan A, Islam A . Acute megakaryoblastic leukaemia or acute myelofibrosis? Br J Haematol 1979; 43: 157\u2013158.","journal-title":"Br J Haematol"},{"key":"BF2404206_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/modpathol.3800348","volume":"18","author":"A Orazi","year":"2005","unstructured":"Orazi A, O'Malley DP, Jiang J, Vance GH, Thomas J, Czader M et al. Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 2005; 18: 603\u2013614.","journal-title":"Mod Pathol"},{"key":"BF2404206_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00277-004-0881-8","volume":"83","author":"J Thiele","year":"2004","unstructured":"Thiele J, Kvasnicka HM, Zerhusen G, Vardiman J, Diehl V, Luebbert M et al. Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up. Ann Hematol 2004; 83: 513\u2013521.","journal-title":"Ann Hematol"},{"key":"BF2404206_CR49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0145-2126(01)00055-8","volume":"25","author":"DP Steensma","year":"2001","unstructured":"Steensma DP, Hanson CA, Letendre L, Tefferi A . Myelodysplasia with fibrosis: a distinct entity? Leuk Res 2001; 25: 829\u2013838.","journal-title":"Leuk Res"},{"key":"BF2404206_CR50","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326\u20134335.","journal-title":"Blood"},{"key":"BF2404206_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","volume":"111","author":"FM Abu-Duhier","year":"2000","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190\u2013195.","journal-title":"Br J Haematol"},{"key":"BF2404206_CR52","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1055\/s-2002-34942","volume":"127","author":"C Muller-Tidow","year":"2002","unstructured":"Muller-Tidow C, Steur C, Mizuki M, Schwable J, Brandts C, Berdel WE et al. Mutationen des Wachstumsfaktor-Rezeptors Flt3 bei Akuter Myeloischer Leukamie \u2013 Transformation myeloischer Zellen durch Ras-abhangige und Ras-unabhangige Mechanismen. Deutsche Medizinische Wochenschrift 2002; 127: 2195\u20132200.","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"BF2404206_CR53","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2002-08-2474","volume":"101","author":"A Kawasaki","year":"2003","unstructured":"Kawasaki A, Matsumura I, Kataoka Y, Takigawa E, Nakajima K, Kanakura Y . Opposing effects of PML and PML\/RAR alpha on STAT3 activity. Blood 2003; 101: 3668\u20133673.","journal-title":"Blood"},{"key":"BF2404206_CR54","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1182\/blood-2004-09-3701","volume":"105","author":"I Melzner","year":"2005","unstructured":"Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535\u20132542.","journal-title":"Blood"},{"key":"BF2404206_CR55","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2002-06-1735","volume":"101","author":"O Galm","year":"2003","unstructured":"Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG . SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 2784\u20132788.","journal-title":"Blood"},{"key":"BF2404206_CR56","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/sj.leu.2403741","volume":"19","author":"C Mestre","year":"2005","unstructured":"Mestre C, Rubio-Moscardo F, Rosenwald A, Climent J, Dyer MJ, Staudt L et al. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia 2005; 19: 1082\u20131084.","journal-title":"Leukemia"},{"key":"BF2404206_CR57","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood-2004-03-1216","volume":"105","author":"P Walrafen","year":"2005","unstructured":"Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P . Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005; 105: 600\u2013608.","journal-title":"Blood"},{"key":"BF2404206_CR58","doi-asserted-by":"publisher","first-page":"18375","DOI":"10.1074\/jbc.275.24.18375","volume":"275","author":"F Verdier","year":"2000","unstructured":"Verdier F, Walrafen P, Hubert N, Chretien S, Gisselbrecht S, Lacombe C et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000; 275: 18375\u201318381.","journal-title":"J Biol Chem"},{"key":"BF2404206_CR59","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1182\/blood-2004-07-2733","volume":"105","author":"T Montoye","year":"2005","unstructured":"Montoye T, Lemmens I, Catteeuw D, Eyckerman S, Tavernier J . A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach. Blood 2005; 105: 4264\u20134271.","journal-title":"Blood"},{"key":"BF2404206_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/ng0693-124","volume":"4","author":"HW Tsui","year":"1993","unstructured":"Tsui HW, Siminovitch KA, de Souza L, Tsui FW . Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993; 4: 124\u2013129.","journal-title":"Nat Genet"},{"key":"BF2404206_CR61","doi-asserted-by":"crossref","unstructured":"Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK\/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005: [E-pub June 27, 2005].","DOI":"10.1038\/sj.onc.1208788"},{"key":"BF2404206_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S1521-6616(03)00208-0","volume":"109","author":"M Esteller","year":"2003","unstructured":"Esteller M . Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003; 109: 80\u201388.","journal-title":"Clin Immunol"},{"key":"BF2404206_CR63","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ijc.20521","volume":"112","author":"Y Oshimo","year":"2004","unstructured":"Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 2004; 112: 1003\u20131009.","journal-title":"Int J Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404206","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:34:17Z","timestamp":1648780457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6,1]]}},"alternative-id":["BF2404206"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404206","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,6]]},"assertion":[{"value":"15 September 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}